Aethlon medical announces publication of preclinical data showing ability of the hemopurifier® to remove extracellular vesicles and micrornas from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys

Results support future study of the hemopurifier® as part of a machine perfusion circuit to further assess its association with function of retrieved kidneys san diego , aug. 27, 2024 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication in preprint of an in vitro study in biorxiv on august 24, 2024, entitled, "the hemopurifier® removes extracellular vesicles and micrornas from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys." aethlon medical's hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids, qualities which have potential applications in oncology and infectious diseases, as well as in the organ transplant setting.
AEMD Ratings Summary
AEMD Quant Ranking